anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: To determine the contribution of ultra-processed foods (UPFs) to overall macronutrient intake and their association with anthropometric measurements, and to explore the perceptions regarding UPF consumption among young adults in Puducherry, India.
METHODS: This study included 630 participants from three colleges selected using multistage cluster sampling. Following the demonstration of portion estimation, dietary data from previous day were collected using a Google Form-based tool. The participant's anthropometric measures were taken. Food items were classified into NOVA groups and intake analysis was performed using DietSoft software. The participants with low and high consumption were identified and focus group discussions were conducted in each group using criterion sampling.
RESULTS: Of all the participants, 178 (28.3%) were overweight or obese. UPF contributed 9.3% of total energy intake and 2.8% protein, 9.9% fat, and 9.9% carbohydrates. The most consumed UPFs were biscuits, wafers (25%), and potato chips(16.2%). No significant association was found between anthropometric measures and UPF consumption. Qualitative findings revealed four major themes, further explained using the socio-ecological framework.
CONCLUSION: UPF consumption in the region was lower than that reported in other global and Indian studies. While our study did not find a significant association between UPF consumption and anthropometric measures, there is a concerning shift from traditional diets to increased UPF reliance, driven by convenience and commercial factors. Addressing this is crucial for healthier choices and combating non-communicable diseases during this pivotal life stage.
CLOZARIL has potent anticholinergic effects. Treatment with CLOZARIL can result in CNS and peripheral anticholinergic toxicity. Use with caution in the presence of narrow-angle glaucoma, concomitant anticholinergic medications, prostatic hypertrophy, or other conditions in which anticholinergic effects can lead to significant adverse reactions.

Treatment with CLOZARIL can result in gastrointestinal adverse reactions, including constipation, intestinal obstruction, fecal impaction, and paralytic ileus. Such reactions can be fatal. Constipation should be initially treated by ensuring adequate hydration and use of ancillary therapy such as bulk laxatives. Consultation with a gastroenterologist is advisable in more serious cases.
Sham transcranial direct current stimulation (tDCS) will be delivered using a Soterix mini-CT device. Participants receiving this treatment will be administered 2 milliamperes (mA) of current for 1 minute to simulate the experience of tDCS, after which the current will be ramped down to zero for the remaining 19 minutes of the session with the anode electrode placed over F3 and the cathode electrode placed over Fp2 (according to the 1020 system). The tDCS will be paired with 60 minutes of speech-language therapy focusing simultaneously improving auditory comprehension and behavioral attention. All study participants will receive 10 sessions of this combination treatment with no more than one session per day 2-3 times per week.
Pre-treatment spirometry measurement will be performed, intervention with a one time 5mg nebulized albuterol treatment will be administered with the experimental "T-piece Nebulizer" (Hudson RCI® Micro Mist® nebulizer Teleflex Medical®, Research Triangle Park, NJ). Treatment will be administered over 10 minutes. Following this therapy, post-treatment spirometry measurement will be performed.
Managing renal fibrosis is challenging owing to the complex cell signaling redundancy in diseased kidneys. Renal fibrosis involves an immune response dominated by macrophages, which activates myofibroblasts in fibrotic niches. However, macrophages exhibit high heterogeneity, hindering their potential as therapeutic cell targets. Herein, we aimed to eliminate specific macrophage subsets that drive the profibrotic immune response in the kidney both temporally and spatially. We identified the major profibrotic macrophage subset (Fn1+Spp1+Arg1+) in the kidney and then constructed a 12-mer glycopeptide that was designated as bioactivated in vivo assembly PK (BIVA-PK) to deplete these cells. BIVA-PK specifically binds to and is internalized by profibrotic macrophages. By inducing macrophage cell death, BIVA-PK reshaped the renal microenvironment and suppressed profibrotic immune responses. The robust efficacy of BIVA-PK in ameliorating renal fibrosis and preserving kidney function highlights the value of targeting macrophage subsets as a potential therapy for patients with CKD.
The invention provides the new medicine use of Sha Kuilawei, be specifically related to Sha Kuilawei by suppressing I type alveolar epithelial cells apoptosis, do you promote the glycosylated end-product receptor (receptor of I type alveolar epithelial cells? for? advanced? glycation? endproducts, RAGE) thus expression suppress acute lung injury/acute respiratory distress syndrome (ALI/ARDS) and the developing of pulmonary fibrosis so that prevention or treat ALI/ARDS and pulmonary fibrosis. In above-mentioned application, its injection using dosage scope is 50mg～2000mg; Preferably 50～1000mg. It orally uses dosage range is 200mg～6000mg; Preferably 400～6000mg.
Participants will receive JNJ-64417184 oral tablet in fed conditions (high-fat meal) in treatment period 1; followed by JNJ-64417184 oral tablet in fed conditions (low-fat meal) in treatment period 2; followed by JNJ-64417184 oral tablet under fasted condition in treatment period 3; followed by JNJ-64417184 oral tablet in fed conditions (Ensure Original) in treatment period 4, on Day 1 of each treatment period. A washout period of at least 7 days will be maintained between each treatment period.
FIELD: medicine. SUBSTANCE: method involves administering intracutaneously and into sublaying tissues biologically active substances using ultrasound. The biologically active substances are extracted from elecampane roots by means of 40% ethanol solution. Paravertebral zones of cervical segment of the vertebral column and suprabrachial areas are the regions for injecting the biologically active substances. Ultrasound is generated by physiotherapeutic apparatus. One procedure duration is equal to 10 min. The whole treatment course consists of 10 procedures. EFFECT: enhanced effectiveness of treatment course. 4 tbl
Provided herein is a pharmaceutical composition comprising: (a) an effective amount of one or more of acetylcholinesterase inhibitors) or a pharmaceutically effective salt thereof; and (b) an effective amount of one or more NMDA-antagonist(s). Also provided is the use of the above composition for the manufacture of a medicament for the treatment of mild cognitive impairment or dementia. Provided herein is a pharmaceutical composition comprising: (a) an effective amount of one or more of acetylcholinesterase inhibitors) or a pharmaceutically effective salt thereof; and (b) an effective amount of one or more NMDA-antagonist(s). Also provided is the use of the above composition for the manufacture of a medicament for the treatment of mild cognitive impairment or dementia. <SDOCL LA=EN> Claims 1. A synergistic pharmaceutical composition for treating mild cognitive impairment or dementia comprising (a) a therapeutically effective amount of one or more of acetylcholinesterase inhibitors or a pharmaceutically effective salt thereof selected from the group consisting of Tacrine, Donepezil, Rivastigmine and Galantamine or mixtures thereof; and (b) a therapeutically effective amount of Memantine. 2. The composition according to claim 1 wherein component (a) is Donepezil. 3. The composition according to claim 1 wherein component (a) and component (b) are in the same delivery vehicle. 4. The composition according to claim 1 wherein component (a) and component (b) are in different delivery vehicles. 5. The use of a synergistic composition comprising: (a) a therapeutically effective amount of one or more acetylcholinesterase inhibitors or a pharmaceutically acceptable salt thereof selected from the group consisting of Tacrine, Donepezil.
An illustrative optical measurement system includes a light source configured to emit light directed at a target within a user. The system further includes a detector configured to detect photon arrival times for photons of the light after the light is scattered by the target. The system further includes a processor configured to determine, based on the photon arrival times, histogram data associated with the target, the histogram data including noise. The processor is further configured to determine, based on the photon arrival times, a random matrix corresponding to the photon arrival times. The processor is further configured to determine, based on the random matrix, a noise distribution representing a distribution of the noise within the histogram data. The processor is further configured to generate clean histogram data using the noise distribution to filter at least a portion of the noise from the histogram data.
PCT No. PCT/DE96/01253 Sec. 371 Date Apr. 23, 1998 Sec. 102(e) Date Apr. 23, 1998 PCT Filed Jul. 8, 1996 PCT Pub. No. WO97/04117 PCT Pub. Date Feb. 6, 1997The invention concerns an adenovirus vector for liver specific gene therapy; fields of application in medicine are the treatment of gene defects and tumour diseases of the liver and molecular biology. The vector according to the invention is marked by the fact that a therapeutic gene is coupled with a liver-specific promoter consisting of enhancer elements of the hepatitis B virus and an enhancerless minimum promoter and is optionally surrounded by SAR elements wherein the promoter is inserted into the adenovirus genome.
Atorvastatin (80 mg), oral administration daily. Ezetimibe (10 mg), oral administration daily, from week 4 if LDL-C is ≥ 70 mg/dL (1.8mmol/L) at week 4.
The present invention provide a therapeutic agent for dermatitis, particularly a therapeutic agent for atopic dermatitis, having high safety and showing little adverse reaction such as steroidal agent. The present invention relates to a therapeutic agent for dermatitis, particularly a therapeutic agent for atopic dermatitis, containing a compound represented by the following formula (I) or a pharmaceutically acceptable salt or hydrate thereof as an effective ingredient. <CHEM>  (In the formula, R is hydrogen or halogen.) The therapeutic agent for dermatitis according to the present invention significantly and dose-dependently suppressed the antigen-induced swelling reaction in ear of mouse recognized as an animal model for atopic dermatitis. Also, the agent suppressed the antigen-induced flare reaction of mice occurred with the swelling reaction. In addition, the adverse reaction to the skin was not observed. The therapeutic agent for dermatitis of this invention is, therefore, is very useful as a drug for atopic dermatitis with high safety.
This randomized control trial will be conducted at the USF Department of Orthopaedics at the USF Health Morsani Center after receiving approval from the USF Institutional Review Board. Patients will be evaluated Carpal Tunnel Syndrome and screened as candidates for Carpal Tunnel Release surgery, following the inclusion and exclusion criteria. The Medical Record Number (MRN) will be used to randomly assign into treatment interventions. Group 1 and group 2 will receive 10cc and 20cc of intra-operative intra-carpal tunnel anesthetic injection, respectively. Postoperatively, patients will be prescribed an opioid pain medication in congruence with current standard medical practice. Patients will be contacted at 24-hours, 48-hours, 72-hours, and at 2-week clinic follow-up by research staff and will be evaluated for pain levels through the LIKERT scale and pain management through use of prescribed and supplemental pain medications. All data will be analyzed through SPSS v25.
1383427 Detergent bath composition PROCTER & GAMBLE CO 29 June 1972 [29 June 1971] 30517/72 Heading C5D A granular free-flowing detergent bath composition comprises a water-soluble synthetic organic detergent (A) and a microencapsulated emollient bath oil (B) having an encapsulating wall material which is soluble in water at a temperature within the range from 75‹ to 115‹ F. to release therefrom the emollient bath oil, the composition containing 37 to 80% by wt. of microencapsulated emollient relative to the total composition, and not more than 5% by wt. of free moisture and having a pH value in aqueous solution within the range from 5 to 10. The bath oil may be chosen from a mineral oil, a vegetable oil, a lanolin alcohol or ester, a silicone oil, isopropyl myristate, isopropyl palmitate and decaglycerol. A mixture of mineral oil and isopropyl myristate is preferred. The wall material comprises 10 to 30% by wt. of the microcapsule and may consist of gelatine, gelatine/gum arabic or gelatine/sodium alginate. The organic detergent (A) may be an anionic, nonionic, ampholytic or zwitterionic surfactant or mixture thereof. An organic and/or inorganic alkaline builder salt (C) may be present. The ratio of (A) to (C) is from 2 : 1 to 1 : 10. The microcapsules are dry mixed with spray-dried granules of the detergent components or with the mixed powdered detergent components which may contain soap and pyrogenic silica. A preferred detergent is sodium alkyl glycerol ether sulphonate which is soap curd-dispersing and does not cause emollient deposition. The detergent granules should have a particle size of 0À1 mm. to 1À5 mm. Conventional detergent adjuvants may be present.
Patients receive cardiac monitor implants then undergo standard of care RT or CRT at the discretion of the treating physician. Patients also undergo blood sample collection at baseline, 4 weeks, 3, 9, and 12 months.
H:\AMnI\Inenvoven\NRPortb\DCC\AM'h5O59376_ .DOC-9/04/2013 THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS: 1. A method of preventing or inhibiting vertebral compression fractures comprising: providing a composition comprising a PDGF solution disposed in a biocompatible matrix; and, applying the composition to at least one vertebral body. 2. The method of claim 1, wherein applying comprises injecting the at least one vertebral body with the composition. 3, The method of claim 1, wherein the at least one vertebral body comprises a high risk vertebrae body. 4. A method for promoting or accelerating bone formation in a vertebral body comprising: providing a composition comprising a PDGF solution disposed in a biocompatible matrix; and, applying the composition to at least one vertebral body. 5. The method of claim 4, further comprising providing at least one pharmaceutical composition; and, administering the pharmaceutical composition locally to a patient. 6. The method of claim 5, wherein administering the pharmaceutical composition locally comprises disposing the pharmaceutical composition in or around the at least one vertebral body. 7. The method of claim 4, further comprising providing at least one pharmaceutical composition; and, administering the pharmaceutical composition systemically to a patient. 8. The method of claim 7, wherein administering the pharmaceutical composition systemically comprises oral administration, intravenous administration, or combinations thereof. 9. The method of claim 5, wherein the patient is an individual with osteoporosis. 10. The method of claim 5, wherein the patient is an individual that has undergone kyphoplasty or vertebroplasty. WO 2008/151193 PCT/US2008/065666 11. A composition for promoting bone formation in a vertebral body comprising: a solution comprising platelet derived growth factor (PDGF); a biocompatible matrix; and, 5 at least one contrast agent, wherein the solution and the contrast agent are disposed in the biocompatible matrix. 12. The composition of claim 11, wherein the at least one contrast agent comprises a cationic contrast agent, an anionic contrast agent, a non-ionic contrast agent, or combinations thereof. 13. The composition of claim 11, wherein the contrast agent comprises an iodo-compound. 14. The composition of claim 13, wherein the iodo-compound comprises (S)-NN'-bis[2 hydroxy-1-(hydroxymethyl)-ethyl]-2,4,6-triiodo-5-lactamidoisophthalamide or derivatives thereof. 15. Use of a composition as in any one of claims 11-14 in the preparation of a medicament useful for promoting bone formation in at least one vertebral body. 16. Use of a composition comprising a solution comprising PDGF and a biocompatible matrix, wherein the solution is disposed in the biocompatible matrix, in the preparation of a medicament useful for promoting bone formation in at least one vertebral body.
Carcinogenesis

Carcinogenicity was evaluated in CD-1 mice and Sprague-Dawley rats. In the mouse study, ertugliflozin was administered by oral gavage at doses of 5, 15, and 40 mg/kg/day for up to 97 weeks in males and 102 weeks in females. There were no ertugliflozin-related neoplastic findings at doses up to 40 mg/kg/day (approximately 50 times human exposure at the maximum recommended human dose [MRHD] of 15 mg/day based on AUC). In the rat study, ertugliflozin was administered by oral gavage at doses of 1.5, 5, and 15 mg/kg/day for up to 92 weeks in females and 104 weeks in males. Ertugliflozin-related neoplastic findings included an increased incidence of adrenal medullary pheochromocytoma (PCC) in male rats at 15 mg/kg/day. Although the molecular mechanism remains unknown, this finding may be related to carbohydrate malabsorption leading to altered calcium homeostasis, which has been associated with PCC development in rats and has unclear relevancy to human risk. The no-observed-effect level (NOEL) for neoplasia was 5 mg/kg/day (approximately 16 times human exposure at the MRHD of 15 mg/day, based on AUC).

Mutagenesis

Ertugliflozin was not mutagenic or clastogenic with or without metabolic activation in the microbial reverse mutation, in vitro cytogenetic (human lymphocytes), and in vivo rat micronucleus assays.

Impairment of Fertility

In the rat fertility and embryonic development study, male and female rats were administered ertugliflozin at 5, 25, and 250 mg/kg/day. No effects on fertility were observed at 250 mg/kg/day (approximately 480 and 570 times male and female human exposures, respectively, at the MRHD of 15 mg/day based on AUC comparison).
BACKGROUND: Misuse of prescription opioids is a well-established contributor to the US opioid epidemic. The primary objective of this study was to identify which level of care delivery (ie patient, prescriber, or hospital) produced the most unwarranted variation in opioid prescribing after common surgical procedures.
STUDY DESIGN: Electronic health record data from a large multihospital healthcare system were used in conjunction with random-effect models to examine variation in opioid prescribing practices after similar inpatient and outpatient surgical procedures between October 2019 and September 2021. Unwarranted variation was conceptualized as variation resulting from prescriber behavior unsupported by evidence. Covariates identified as drivers of warranted variation included characteristics known to influence pain levels or patient safety. All other model variables, including prescriber specialty and patient race, ethnicity, and insurance status were characterized as potential drivers of unwarranted variation.
RESULTS: Among 25,188 procedures with an opioid prescription at hospital discharge, 53.5% exceeded guideline recommendations, corresponding to 13,228 patients receiving the equivalent of >140,000 excess 5 mg oxycodone tablets after surgical procedures. Prescribing variation was primarily driven by prescriber-level factors, with approximately half of the total variation in morphine milligram equivalents prescribed observed at the prescriber level and not explained by any measured variables. Unwarranted covariates associated with higher prescribed opioid quantity included non-Hispanic Black race, Medicare insurance, smoking history, later hospital discharge times, and prescription by a surgeon rather than a hospitalist or primary care provider.
CONCLUSIONS: Given the large proportion of unexplained variation observed at the provider level, targeting prescribers through education and training may be an effective strategy for reducing postoperative opioid prescribing.
Study Design Patients with previously untreated Stages III\~IVA (AJCC 6th Edition) of locally advanced NPC, Karnofsky performance status≥70, and good bone marrow, liver and kidney functions (white blood count ≥ 4.0×109/L, platelets ≥ 100×109/L, albumin ≥30 g/L , creatinine ≤100μmol/L) were enrolled on this study. Patients younger than 18, those with a prior (within 5 years) or synchronous malignancy were excluded. Pretreatment evaluations consisted of a history and physical, dental and laboratory studies. The clinical stage was determined based on all information provided by examinations including contrast enhanced CT and magnetic resonance imaging (MRI) of head and neck, Chest X-ray, liver sonography, bone scan, and 18F-FDG-PET. All tumors were histologically confirmed except those of distant sites.

Patients who met the eligibility criteria were randomized 1:1:1 into the three treatment arms: conventional chemoradiotherapy (group A), FDG PET/CT -guided dose escalation chemoradiotherapy (group B) and FMISO PET/CT -guided dose escalation chemoradiotherapy (group C). All patients were given concurrent chemoradiotherapy within two weeks of diagnosis. Radiotherapy was delivered using the simultaneous modulated accelerated radiation therapy (SMART) IMRT technique in the dose-escalation treatment arms. Concurrent chemotherapy consisted of cisplatin (20mg / m2 ,iv, d1- 4) and docetaxel (75mg / m2, d1, d8) administered on the 1st and 4th week of treatment. All patients received adjuvant chemotherapy that ranged from 2 to 4 cycles.

Follow-up and statistical analysis Planned patient assessment included physical examination and fiberoptic nasopharyngoscopy every 3 months to 3 years starting at 4 weeks post-treatment. A contrast-enhanced CT or MRI of the head and neck is also obtained at each follow up. After 3 years, the patients were followed yearly thereafter. Suspected recurrences were histologically proven. To assess for distant metastasis, CT of the chest and bone scan were obtained every half a year. During every follow-up visit, treatment toxicity were assessed. Radiotherapy-related toxicities were graded according to the Acute and the Late Radiation Morbidity Scoring Criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Chemotherapy-related toxicities (except nausea or alopecia) were graded by the criteria of the WHO.

All events were measured from the date of randomization. OS was defined as the time from the date of radiotherapy to death or the latest date known to be alive. Durations were calculated from the end of treatment. The Kaplan-Meier method was used to calculate the actuarial rates of local control, DFS and OS. The χ2 test was used for comparing incidence rates and categorical variables and Student's t-test was used for comparing the means of continuous variables.